GlassScriptPhysician profile
Katy Miller
NPI 1487285839
$3,378.15
in general payments reported to CMS, 2019-2025
22 companies · $2,140 in 2025
The $2,140 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.41 · 2023: $438 · 2024: $784 · 2025: $2,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,361.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $531.11 | 2024-2025 | |
| Novo Nordisk INC | $479.31 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $437.05 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $263.90 | 2023-2024 | Shingrix, Bexsero, Trelegy Ellipta |
| Amgen INC. | $263.27 | 2024-2025 | Evenity, Repatha, Repatha |
| Insulet Corporation | $229.55 | 2025 | Omnipod |
| Astellas Pharma US INC | $189.49 | 2024-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $150.01 | 2024-2025 | Austedo Xr, Ajovy |
| Gilead Sciences, INC. | $147.18 | 2023 | Epclusa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.18 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $121.54 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $116.74 | 2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.92 | 2025 | Xifaxan |
| Hologic Sales and Service, LLC | $32.49 | 2022-2023 | Aptima |
| Irhythm Technologies, INC. | $30.58 | 2023 | Zio Xt Patch |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $29.32 | 2025 | Rexulti |
| Lundbeck LLC | $27.94 | 2025 | Rexulti |
| Pfizer INC. | $22.87 | 2025 | |
| Xeris Pharmaceuticals, INC. | $21.91 | 2024 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $19.46 | 2025 | Nexletol |
| Lilly USA, LLC | $19.44 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $14.89 | 2024 | Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katy Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.